

BEST OF SABCS CROATIA, Zagreb 20. – 21. February 2026.

PROGRAMME

FRIDAY, 20.2.2026.

14:30 Welcome and Introductions

14:40 – 15:50 Section 1.

- Z. MARUŠIĆ** Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stageII/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181/CompassHER2 pCR trial
- M. JAZVIĆ** Prognostic Markers in Residual Tumors after Neoadjuvant Chemotherapy (NACT) fo Early Triple-Negative Breast Cancer (TNBC)– a Pooled Analysis from nine Neoadjuvant GBG/AGO-B trials
- S. PLEŠTINA** Effect of Adjuvant Carboplatin Intensified Chemotherapy versus StandardChemotherapy on Survival in Women with High-Risk Early-Stage Triple-Negative Breast Cancer (CITRINE): A Phase 3 Randomized Trial .
- J. FLAM** Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial
- T. SILOVSKI** Sacituzumab Govitecan vs Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2– (IHC 0, 1+, 2+/ISH–) Metastatic Breast Cancer: Primary Results From ASCENT-07

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

15:50 - 16:20

Satellite Symposium: Eli Lilly

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

16:20 – 16:50

Satellite Symposium: Novartis

16:50 – 17:20 Coffee break

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

17:20 – 17:50

Satellite Symposium: Roche

17:50 – 18:50 Section 2.

- J. CORTES** Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial.
- M. BAN** Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.
- A. STRIKIĆ** Efficacy Analysis of the Randomized Phase III DETECT Trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2 positive and Hormone Positive Metastatic Breast cancer .
- N. ŠARIĆ** Radiation therapy or endocrine therapy

18:50 End of program

SATURDAY, 21.2.2026.

9:00 – 10:15 Section 3.

- S. TOMIĆ** HER2 low/ultralow: what the pathologist sees
- B. PETRIĆ MIŠE** DESTINY-Breast11 safety: neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer

- A. BUDISAVLJEVIĆ** Trastuzumab deruxtecan vs trastuzumab emtansine in pts with high risk HER2+ primary breast cancer with residual disease after neoadj th: interim analysis of Destiny -Breast 05.
- N. DEDIĆ PLAVETIĆ** HER2CLIMB-05: A randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer
- P. SERTIĆ** Cardiotoxicity of breast cancer novel therapies
- J. JOVIĆ ZLATOVIĆ** Impact of Immune Checkpoint Inhibition on Fertility in Young Women with Early Triple-Negative Breast Cancer receiving neoadjuvant Chemotherapy: A Prospective Substudy of the NSABP B-59/GeparDouzeTrial

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

10:15 – 10:45 Satellite Symposium Novartis

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

10:45 - 11:15 Satellite Symposium Eli Lilly

11:15 – 11:35 Coffee break

11:35 – 12:50 Section 4.

- I. MILAS** Axillary surgery in breast cancer with one to three sentinel node macrometastases and breast-conserving surgery: Secondary results of the INSEMA trial
- A. DUJMOVIĆ** More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy-primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R) study
- K. ANTUNAC** Advances in breast radiotherapy: Less is more!
- M. SOČE** Should we irradiate the IM Nodes: Settling the Issue
- T. MLINARIĆ KOPRIVANAC**
- Repeat breast conservation with re-irradiation: What is the data and how do we do it?

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

12:50 – 13:10

Satellite Symposium: Pfizer

13:10 – 14:00 Lunch/Break

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

14:00 – 14:45

Satellite Symposium Astra Zeneca

14:45 – 15:25 Section 5.

I. BIONDIĆ

Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

M. PRUTKI

Effect of preoperative breast MRI Staging on Local regional recurrence (LRR) in early stage Breast cancer: ALLiance AO11104/ACRIN6694

D. HUIĆ

FDG-PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE ECOG-ACRIN EA1183

15:25 - 16:15 CLINICAL CONTROVERSIES:

Management of the Axilla in Multidisciplinary Care

R. ŽIC

De-escalation of axillary surgery after NAC in clinically node positive patients

K. ANTUNAC

De-Escalation of Regional Nodal Irradiation after NAC in Clinically Node Positive Patients

16:15 – 16:35 Coffee break

16:35 - 17:15 Section 6. YEAR IN THE REVIEW

Moderator: **Eduard Vrdoljak**

M. BAŠIĆ KORETIĆ: Early breast cancer

E. VRDOLJAK: Advanced breast cancer

17:15 - 17:30 WHAT WILL WE DO ON MONDAY MORNING?

17:30 Summary and Closing Remarks

17:35 End of the Symposium

